10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
A study published in the April 25 issue of Arthritis Care and Research, shows that patients with PsA have a 55% increase in the risk of incident cardiovascular events. The overall risk of cardiovascular disease is 43% greater than that of the general population. By comparison, PsA patients face a 31% increased risk of congestive heart failure, 38% increased risk of incident cerebrovascular events and 57% increased risk of developing myocardial infarction. “Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies.” Ari Polachek, M.D., Zahi Touma, M.D., Ph.D., et. al. Arthritis Care and Research. April 25, 2016. DOI: 10.1002/acr.22926.Â
“Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies.” Ari Polachek, M.D., Zahi Touma, M.D., Ph.D., et. al. Arthritis Care and Research. April 25, 2016. DOI: 10.1002/acr.22926. Framingham Heart Study, Cardiovascular Disease (10-year risk)
“Atherosclerosis in psoriatic disease: latest evidence and clinical implications.” Lihi Eder and Dafna D. Gladman, Therapeutic Advances in Musculoskeletal Disease. October 2015. DOI: 10.1177/1759720X15591801
“Atherosclerosis in psoriatic disease: latest evidence and clinical implications.” Lihi Eder and Dafna D. Gladman, Therapeutic Advances in Musculoskeletal Disease. October 2015. DOI: 10.1177/1759720X15591801
“Self-reported depression in psoriasis is associated with subclinical vascular diseases.” Aberra TM, Joshi AA, et al. Atherosclerosis. May 27, 2016. DOI: 10.1016/j.atherosclerosis.2016.05.043.
"Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis." Egeberg A, Bruun LE, et. al. Journal of the American Academy of Dermatology. June 6, 2016. DOI: 10.1016/j.jaad.2016.02.1227
“Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions.” Haroon M, Rafiq Chaudhry AB, Fitzgerald O. Journal of Rheumatology. February 2016. DOI: 10.3899/jrheum.150757.
"The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients." Ku SH, Kwon W.J. et. al. Annals of Dermatology. May 25, 2016. DOI: 10.5021/ad.2016.28.3.360.
"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis." The Lancet. Jan 9, 2010. DOI: 10.1016/S0140-6736(09)61717-7
“Managing Cardiovascular Disease in Patients with Rheumatoid Arthritis?” Rheumatology Nurse Practice Volume 2, Issue 1."Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study," Hyon K Choi, MD, Miguel A Hernán, MD, et. al. The Lancet. April 6, 2002. DOI: http://dx.doi.org/10.1016/S0140-6736(02)08213-2
"Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis." Hjuler KF, Bøttcher M, et. al. JAMA Dermatology. July 7, 2016. DOI: 10.1001/jamadermatol.2016.1984. “Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis.” Piaserico S, Osto E, et al. Atherosclerosis. May 21, 2016. DOI: 10.1016/j.atherosclerosis.2016.05.036.
